ARQT · Arcutis Biotherapeutics, Inc.

ARQT Arcutis Biotherapeutics, Inc. NMS

$24.38 -0.21 (-0.85%)

Extended · +1.97σ Grade B

+ Compare Set alert Open in Sniper

132-Day TAO Zones

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Key statistics

Mkt cap $3.0B

P/E ttm —

Fwd P/E 21.1

Beta 1.52

Day range $24.38

52w range $19.30 – $30.75

Avg vol 1.6M

RSI(2) 80.6

ROE -1.4%

Net mgn -0.6%

FCF mgn 0.9%

Debt/Eq 0.60

Div yld —

Sector Healthcare

Industry Biotechnology

Next earn 2026-08-05

Matrix setup grades

Long —

score 9 · tech 9 / 80 · support 0 / 20

above KC1 lower, +1.96 ATR from EMA21 · no notable pattern

Short B

score 40 · tech 40 / 80 · support 0 / 20

KC2 upper, +1.96 ATR from EMA21 · no notable pattern

ℹ️ Stretched (KC2): stop is set a little wider to avoid a whipsaw, so the reward/risk reads a bit lower by design.

· KC2 upper stretch — standard mean-reversion tier
· RSI hook from overbought (65)
· Stochastic bear cross in overbought

Valuation & accounting

DCF + multiples · long-term lens

Intrinsic (DCF)

$2.43

Fair-value range

$0.56 – $9.02

Margin of safety

-785%

Verdict

Overvalued

Accounting quality Weak

✓ More cash than debt
✓ Quick ratio 2.85 (antifragile)
✓ Current ratio 3.17 (antifragile)
✓ Gross margin 91% (pricing power)

⚠ Negative retained earnings
⚠ Receivables growing faster than revenue
⚠ Stock comp 11% of revenue (heavy dilution)

Price implies ~77% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Options · swing

See more →

CALL $25 2026-07-17

$1.10

PUT $25 2026-07-17

$1.65

Insider activity

See more →

No Form 4 filings in the last 30 days.

Earnings

See more →

Last reported: 2026-05-06
EPS (act / est): -0.09 / -0.06
Surprise: -55.2%
Next report: 2026-08-05

About

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion p…